Senior insider sale
CHIEF MEDICAL OFFICER at ENLIVEN THERAPEUTICS, INC. — senior position signals high conviction
$2.50M
90K shares
What this filing means
COLLINS HELEN LOUISE plans to sell 90K shares of ENLIVEN THERAPEUTICS, INC. valued at approximately $2.50M. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 3/9/2026ACC: 0001974158-26-000023
Officer· CHIEF MEDICAL OFFICER
Since Feb 2026
90K
Shares to sell
$2.50M
Approx. market value
45K
Acquired (3 months)
1
Planned
2 completed
Securities Acquired — Last 3 Months1
Stock Options
N/A
8/9/2022
45KTotal acquired45K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
8/9/2022 | Stock Options N/A | 45K | — |
| Total | 45K | ||
Planned & Completed Dispositions3
Completed
—Completed
Units to sell
5K
Market value
$130.9K
2/17/2026
—Completed
Units to sell
40K
Market value
$1.05M
2/17/2026
Planned — Approximate Date
NasdaqPlanned
Units to sell
45K
Market value
$1.32M
3/9/2026
Total
Units
90K
Value
$2.50M
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
2/17/2026 | 5K | $130.9K | — | Completed |
2/17/2026 | 40K | $1.05M | — | Completed |
| Planned — Approximate Date | ||||
3/9/2026 | 45K | $1.32M | Nasdaq | Planned |
| Total | 90K | $2.50M | ||